[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620165":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":34,"responsibleParty":325,"collaborators":30,"id":327,"slug":328,"hasResults":329,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":30,"eligibilityCriteria":333,"healthyVolunteers":329,"sex":334,"minAge":335,"maxAge":336,"enrollmentInfo":337,"targetDuration":30,"studyType":340,"phases":341,"briefSummary":343,"conditions":344,"keywords":347,"overallStatus":37,"whyStopped":30,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":369},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single arm study","EXPERIMENTAL","This study will enroll pediatric patients (≥ 1 and \\\u003C 18 years of age) with newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation",[13],"Drug: Asciminib single agent",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Asciminib single agent","Asciminib (labelled as ABL001) administered as 40 mg tablet (adult formulation) or as 1 mg film-coated granules mini-tablets (pediatric formulation)",[9],[21],"ABL001",[23],{"name":24,"affiliation":24,"role":25},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[27,32],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","1-888-669-6682",null,"novartis.email@novartis.com",{"name":24,"role":28,"phone":33,"phoneExt":30,"email":30},"+41613241111",[35,56,72,88,105,117,126,136,144,155,164,175,183,193,201,209,217,227,238,249,257,265,275,285,293,302,307,317],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Rutgers Cancer Institute of New Jersey","RECRUITING","New Brunswick","New Jersey","08901","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-74.45182,40.48622,{"lat":47,"lon":46},[50,53],{"name":51,"role":28,"phone":30,"phoneExt":30,"email":52},"Jesmin Habeeb Mohamed","jsh216@cinj.rutgers.edu",{"name":54,"role":55,"phone":30,"phoneExt":30,"email":30},"Richard DRACHTMAN","PRINCIPAL_INVESTIGATOR",{"facility":57,"status":37,"city":58,"state":58,"zip":59,"country":41,"countryCode":42,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Columbia University Medical Center New York Presbyterian","New York","10032",{"type":44,"coordinates":61},[62,63],-74.00597,40.71427,{"lat":63,"lon":62},[66,70],{"name":67,"role":28,"phone":68,"phoneExt":30,"email":69},"Karishma Sookraj","212-305-6953","kss2158@cumc.columbia.edu",{"name":71,"role":55,"phone":30,"phoneExt":30,"email":30},"Nobuko Hijiya",{"facility":73,"status":37,"city":74,"state":75,"zip":76,"country":41,"countryCode":42,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Cinn Children Hosp Medical Center","Cincinnati","Ohio","45229-3039",{"type":44,"coordinates":78},[79,80],-84.51439,39.12711,{"lat":80,"lon":79},[83,86],{"name":84,"role":28,"phone":30,"phoneExt":30,"email":85},"Lori Backus","lori.backus@cchmc.org",{"name":87,"role":55,"phone":30,"phoneExt":30,"email":30},"Benjamin Mizukawa",{"facility":89,"status":37,"city":90,"state":91,"zip":92,"country":41,"countryCode":42,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Seattle Childrens Hospital","Seattle","Washington","98105",{"type":44,"coordinates":94},[95,96],-122.33207,47.60621,{"lat":96,"lon":95},[99,103],{"name":100,"role":28,"phone":101,"phoneExt":30,"email":102},"Angela Bleeker","206-884-1071","Angela.Bleeker@seattlechildrens.org",{"name":104,"role":55,"phone":30,"phoneExt":30,"email":30},"Todd Cooper",{"facility":106,"status":37,"city":107,"state":108,"zip":109,"country":110,"countryCode":111,"cosmosGeoPoint":112,"geoPoint":116,"contacts":30},"Novartis Investigative Site","Brisbane","Queensland","4101","Australia","AU",{"type":44,"coordinates":113},[114,115],153.02809,-27.46794,{"lat":115,"lon":114},{"facility":106,"status":37,"city":118,"state":119,"zip":120,"country":110,"countryCode":111,"cosmosGeoPoint":121,"geoPoint":125,"contacts":30},"North Adelaide","South Australia","5066",{"type":44,"coordinates":122},[123,124],138.59141,-34.90733,{"lat":124,"lon":123},{"facility":106,"status":37,"city":127,"state":127,"zip":128,"country":129,"countryCode":130,"cosmosGeoPoint":131,"geoPoint":135,"contacts":30},"Rio de Janeiro","20211-030","Brazil","BR",{"type":44,"coordinates":132},[133,134],-43.18223,-22.90642,{"lat":134,"lon":133},{"facility":106,"status":37,"city":137,"state":137,"zip":138,"country":129,"countryCode":130,"cosmosGeoPoint":139,"geoPoint":143,"contacts":30},"São Paulo","04829-310",{"type":44,"coordinates":140},[141,142],-46.63611,-23.5475,{"lat":142,"lon":141},{"facility":106,"status":37,"city":145,"state":146,"zip":147,"country":148,"countryCode":149,"cosmosGeoPoint":150,"geoPoint":154,"contacts":30},"Edmonton","Alberta","T6G 1C9","Canada","CA",{"type":44,"coordinates":151},[152,153],-113.46871,53.55014,{"lat":153,"lon":152},{"facility":106,"status":37,"city":156,"state":157,"zip":158,"country":148,"countryCode":149,"cosmosGeoPoint":159,"geoPoint":163,"contacts":30},"Montreal","Quebec","H3T 1C5",{"type":44,"coordinates":160},[161,162],-73.58781,45.50884,{"lat":162,"lon":161},{"facility":106,"status":37,"city":165,"state":166,"zip":167,"country":168,"countryCode":169,"cosmosGeoPoint":170,"geoPoint":174,"contacts":30},"Zhengzhou","Henan","450003","China","CN",{"type":44,"coordinates":171},[172,173],113.64861,34.75778,{"lat":173,"lon":172},{"facility":106,"status":37,"city":176,"state":30,"zip":177,"country":168,"countryCode":169,"cosmosGeoPoint":178,"geoPoint":182,"contacts":30},"Tianjin","300020",{"type":44,"coordinates":179},[180,181],117.17667,39.14222,{"lat":181,"lon":180},{"facility":106,"status":37,"city":184,"state":30,"zip":185,"country":186,"countryCode":187,"cosmosGeoPoint":188,"geoPoint":192,"contacts":30},"Marseille","13885","France","FR",{"type":44,"coordinates":189},[190,191],5.38107,43.29695,{"lat":191,"lon":190},{"facility":106,"status":37,"city":194,"state":30,"zip":195,"country":186,"countryCode":187,"cosmosGeoPoint":196,"geoPoint":200,"contacts":30},"Paris","75019",{"type":44,"coordinates":197},[198,199],2.3488,48.85341,{"lat":199,"lon":198},{"facility":106,"status":37,"city":202,"state":30,"zip":203,"country":186,"countryCode":187,"cosmosGeoPoint":204,"geoPoint":208,"contacts":30},"Poitiers","86021",{"type":44,"coordinates":205},[206,207],0.34348,46.58261,{"lat":207,"lon":206},{"facility":106,"status":37,"city":210,"state":30,"zip":211,"country":186,"countryCode":187,"cosmosGeoPoint":212,"geoPoint":216,"contacts":30},"Strasbourg","67000",{"type":44,"coordinates":213},[214,215],7.74553,48.58392,{"lat":215,"lon":214},{"facility":106,"status":37,"city":218,"state":30,"zip":219,"country":220,"countryCode":221,"cosmosGeoPoint":222,"geoPoint":226,"contacts":30},"Erlangen","91054","Germany","DE",{"type":44,"coordinates":223},[224,225],11.00783,49.59099,{"lat":225,"lon":224},{"facility":106,"status":37,"city":228,"state":229,"zip":230,"country":231,"countryCode":232,"cosmosGeoPoint":233,"geoPoint":237,"contacts":30},"Roma","RM","00165","Italy","IT",{"type":44,"coordinates":234},[235,236],11.10642,44.99364,{"lat":236,"lon":235},{"facility":106,"status":37,"city":239,"state":240,"zip":241,"country":242,"countryCode":243,"cosmosGeoPoint":244,"geoPoint":248,"contacts":30},"Yokohama","Kanagawa","232-8555","Japan","JP",{"type":44,"coordinates":245},[246,247],139.65,35.43333,{"lat":247,"lon":246},{"facility":106,"status":37,"city":250,"state":30,"zip":251,"country":242,"countryCode":243,"cosmosGeoPoint":252,"geoPoint":256,"contacts":30},"Fukuoka","8128582",{"type":44,"coordinates":253},[254,255],130.41667,33.6,{"lat":255,"lon":254},{"facility":106,"status":37,"city":258,"state":30,"zip":259,"country":242,"countryCode":243,"cosmosGeoPoint":260,"geoPoint":264,"contacts":30},"Saitama","330 8777",{"type":44,"coordinates":261},[262,263],139.65657,35.90807,{"lat":263,"lon":262},{"facility":106,"status":37,"city":266,"state":30,"zip":267,"country":268,"countryCode":269,"cosmosGeoPoint":270,"geoPoint":274,"contacts":30},"Utrecht","3584 CS","Netherlands","NL",{"type":44,"coordinates":271},[272,273],5.12222,52.09083,{"lat":273,"lon":272},{"facility":106,"status":37,"city":276,"state":30,"zip":277,"country":278,"countryCode":279,"cosmosGeoPoint":280,"geoPoint":284,"contacts":30},"Gdansk","80-214","Poland","PL",{"type":44,"coordinates":281},[282,283],18.64912,54.35227,{"lat":283,"lon":282},{"facility":106,"status":37,"city":286,"state":30,"zip":287,"country":278,"countryCode":279,"cosmosGeoPoint":288,"geoPoint":292,"contacts":30},"Wroclaw","50-556",{"type":44,"coordinates":289},[290,291],17.03006,51.10286,{"lat":291,"lon":290},{"facility":106,"status":37,"city":294,"state":30,"zip":295,"country":296,"countryCode":30,"cosmosGeoPoint":297,"geoPoint":301,"contacts":30},"Seoul","03080","South Korea",{"type":44,"coordinates":298},[299,300],126.9784,37.566,{"lat":300,"lon":299},{"facility":106,"status":37,"city":294,"state":30,"zip":303,"country":296,"countryCode":30,"cosmosGeoPoint":304,"geoPoint":306,"contacts":30},"06591",{"type":44,"coordinates":305},[299,300],{"lat":300,"lon":299},{"facility":106,"status":37,"city":308,"state":30,"zip":309,"country":310,"countryCode":311,"cosmosGeoPoint":312,"geoPoint":316,"contacts":30},"Barcelona","08035","Spain","ES",{"type":44,"coordinates":313},[314,315],2.15899,41.38879,{"lat":315,"lon":314},{"facility":106,"status":37,"city":318,"state":30,"zip":319,"country":310,"countryCode":311,"cosmosGeoPoint":320,"geoPoint":324,"contacts":30},"Madrid","28009",{"type":44,"coordinates":321},[322,323],-3.70256,40.4165,{"lat":323,"lon":322},{"type":326,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100620165","phase-2-study-to-determine-the-efficacy-and-safety-of-asciminib-in-pediatric-patients-with-ph-cml-cp-100620165",false,"NCT07354074","Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP","A Phase II, Multicenter, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Asciminib in Pediatric Participants Newly Diagnosed or Previously Treated With Philadelphia Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) With or Without Known T315I Mutation","Key Inclusion Criteria:\n\nParticipants eligible for inclusion in this study must meet all of the following criteria:\n\n1. Signed informed consent must be obtained prior to participation in the study.\n2. Male or female participants 1 and \\\u003C 18 years of age at study enrollment\n3. Diagnosis of CML-CP (Apperley et al 2025) with cytogenetic confirmation of Philadelphia positive (Ph+) chromosome\n4. For participants with CML-CP newly diagnosed within 3 months of screening OR 5 For participants with CML - CP with high risk of developing resistance or intolerance to previous TKI:\n\n   1. Unfavourable response to TKI is defined following the Apperley et al 2025 guidelines as:\n\n      * At three months after the initiation of therapy: BCR::ABL1 ratio \\> 10% IS (if confirmed within 1-3 months)\n      * At six months after the initiation of therapy: BCR::ABL1 ratio \\> 10% IS\n      * At twelve months after initiation of therapy: BCR::ABL1 ratio \\> 1% IS\n      * At any time loss of previous response\n      * At any time emergent resistant BCR::ABL1 mutations or high-risk ACA from prior TKI treatment as per local test results\n   2. Intolerance to TKI is defined as:\n\n      * Non-hematologic intolerance: participants with grade 3 or 4 toxicity while on therapy (in which case the patient is eligible whether or not there was a dose reduction); or with persistent grade 2 toxicity unresponsive to optimal management including dose adjustments (unless dose reduction is not considered in the best interest of the patient if response is already suboptimal)\n      * Hematologic intolerance: participants with grade 3 or 4 toxicity (absolute neutrophil count \\[ANC\\] or platelets) while on therapy that is recurrent after dose reduction to the lowest doses of the TKI\n\n6\\. Evidence of typical BCR::ABL1 transcript \\[e14a2 and\u002For e13a2\\] at the time of screening which are amenable to standardized RQ-PCR quantification.\n\n7\\. Performance status: Karnofsky ≥ 50% for participants ≥ 16 years of age, and Lansky ≥ 50 for participants \\\u003C 16 years of age at the time of screening.\n\nKey Exclusion Criteria:\n\n1. Known second chronic phase (CP) of CML after previous progression to Accelerated Phase (AP)\u002FBlast Phase (BP).\n2. Previous treatment with a hematopoietic stem-cell transplantation.\n3. Patient planned to undergo allogeneic hematopoietic stem cell transplantation\n4. Known presence of a BCR::ABL1 mutation with known resistance to study treatment in accordance with the most recent public version of international CML clinical guidelines (e.g. NCCN CML treatment guidelines v 1.2026 and Apperley et al 2025) any time prior to study entry\n\nOther inclusion\u002Fexclusion criteria may apply.","ALL","1 Year","18 Years",{"count":338,"type":339},50,"ESTIMATED","INTERVENTIONAL",[342],"PHASE2","The aim of this study is to support development of asciminib in the pediatric population (1 to \\\u003C 18 years) with Ph+ CML-CP. The study will evaluate the efficacy and safety of asciminib in pediatric formulation (weigh-based dose, fed state) or adult formulation (fasted) in newly diagnosed and resistant or intolerant Ph+ CML-CP with or without T315I mutation.",[345,346],"Chronic Myelogenous Leukemia","Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive",[348,21,349,350,351,352,353,354,355,356,357,358,359],"Asciminib","Pediatric participants","Philadelphia chromosome positive chronic myeloid leukemia in chronic phase","Ph+ CML-CP","tyrosine kinase inhibitor","TKI","Molecular Response","MR","CML","Chronic phase","T3151","Ph+","2026-08-18",{"date":362,"type":363},"2026-08-20","ACTUAL",{"date":365,"type":363},"2026-04-28",{"date":367,"type":339},"2033-02-23",{"name":24,"class":6},28]